Buscar en
Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)
Toda la web
Inicio Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) The correlation between tumor markers and Ga-68 DOTA-TATE PET/CT findings in pat...
Journal Information
Vol. 40. Issue 3.
Pages 161-166 (May - June 2021)
Share
Share
Download PDF
More article options
Vol. 40. Issue 3.
Pages 161-166 (May - June 2021)
Original Article
The correlation between tumor markers and Ga-68 DOTA-TATE PET/CT findings in patients with advanced medullary thyroid cancer
La correlación entre los marcadores tumorales y los hallazgos de Ga-68 DOTA-TATE PET/CT en pacientes con cáncer medular de tiroides avanzado
Serdar Aricia,
Corresponding author
serdararici@hotmail.com

Corresponding author.
, Sevda Saglampınar Karyagarb, Rabia Uslu Erdemirc, Ruhper Cekina, Muhammed Mustafa Atcıa, Osman Güvenb, Savas Karyagarb, Şener Cihana
a Istanbul Okmeydani Training and Research Hospital, Department of Medical Oncology, Turkey
b Istanbul Okmeydani Training and Research Hospital, Department of Nuclear Medicine, Turkey
c Zonguldak Bulent Ecevit University, Faculty of Medicine, Department of Nuclear Medicine, Turkey
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (4)
Show moreShow less
Tables (5)
Table 1. Patients characteristics.
Table 2. Tumor markers and Ga-68 PET findings.
Table 3. Correlation analysis between tumor markers and Ga-68 PET findings.
Table 4. Calcitonin level in which correlation is impaired.
Table 5. Subgroup analysis for correlation between CEA/calcitonin and whole-body MTV.
Show moreShow less
Abstract
Background

Medullary thyroid cancer (MTC) is a rare type of neuroendocrine tumor. Calcitonin (Ctn) and carcinoembryonic antigen (CEA) are used as markers for medullary thyroid cancer. The aim of the study was to evaluate the importance of serum calcitonin and carcinoembryonic antigen levels in predicting total tumor volume.

Material and methods

Ga-68 DOTA-TATE PET/CT findings such as whole-body somatostatin receptor-expressing metabolic tumor volume (SSR-E MTV) and total lesion volume (SSR-E TLV) were calculated and correlation analysis was done for tumor markers and whole-body SSR-E MTV and TLV.

Results

A total of 28 patients with advanced MTC were included in this retrospective study. In the correlation analysis, there was a statistically significant positive correlation between Ctn and whole-body SSR-E MTV (rho=0.503 and p=0.008). Similarly, significant positive correlation was observed between Ctn and whole-body SSR-E TLV (rho=0.436 and p=0.023). There was a significant positive correlation between CEA and whole-body SSR-E MTV (rho=0.584 and p=0.007). Also, a positive correlation was observed between CEA and whole-body SSR-E TLV (rho=0.436 and p=0.023). These correlations were most marked in patients with Ctn ≥152pg/mL and/or both nodal and bone involvement.

Conclusion

These results could stimulate clinicians to perform Ga-68 PET for treatment decisions, especially in patients with high CEA and Ctn levels at the time of diagnosis.

Keywords:
Medullary thyroid cancer
Metabolic tumor volume
Total lesion volume
Calcitonin and carcinoembryonic antigen
Resumen
Antecedentes

El cáncer medular de tiroides (CTM) es un tipo raro de tumor neuroendocrino. La calcitonina (Ctn) y el antígeno carcinoembrionario (CEA) se utilizan como marcadores para el cáncer medular de tiroides. El objetivo del estudio fue evaluar la importancia de los niveles de calcitonina sérica y antígeno carcinoembrionario en la predicción del volumen total del tumor.

Material y métodos

Se calcularon los hallazgos del Ga-68 DOTA-TATE PET/CT, como el volumen tumoral metabólico expresado del receptor de somatostatina de cuerpo entero (SSR-E MTV) y el volumen total de la lesión (SSR-E TLV) y se hizo un análisis de correlación para los marcadores tumorales y el SSR-E MTV y TLV de cuerpo entero.

Resultados

Un total de 28 pacientes con MTC avanzado fueron incluidos en este estudio retrospectivo. En el análisis de correlación, hubo una correlación positiva estadísticamente significativa entre Ctn y MTV SSR-E de cuerpo entero (rho=0,503 y p=0,008). De manera similar, se observó una correlación positiva significativa entre el Ctn y el TLV SSR-E de cuerpo entero (rho=0,436 y p=0,023). Se observó una correlación positiva significativa entre el CEA y el MTV SSR-E de cuerpo entero (rho=0,584 y p=0,007). También se observó una correlación positiva entre el CEA y el TLV SSR-E de cuerpo entero (rho=0,436 p=0,023). Estas correlaciones fueron más marcadas en los pacientes con Ctn ≥152pg/mL y/o con afectación tanto nodal como ósea.

Conclusión

Estos resultados podrían estimular a los clínicos a realizar una PET de Ga 68 para tomar decisiones de tratamiento, especialmente en pacientes con altos niveles de CEA y Ctn en el momento del diagnóstico.

Palabras clave:
Cáncer medular de tiroides
Volumen tumoral metabólico
Volumen total de la lesión
Calcitonina y antígeno carcinoembriógeno

Article

These are the options to access the full texts of the publication Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos